Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma

Mosunetuzumab (Mosun) is a CD20xCD3 T‐cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. The approved step‐up dose regimen of 1/2/60/30 mg IV is designed to mitigate cytokine release syndrome (CRS) and maximize efficacy in early cycles. A population pharmacokine...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical and translational science Vol. 17; no. 6; pp. e13825 - n/a
Main Authors:	Bender, Brendan, Li, Chi‐Chung, Marchand, Mathilde, Turner, David C., Li, Feifei, Vadhavkar, Shweta, Wang, Bei, Deng, Rong, Lu, James, Jin, Jin, Li, Chunze, Yin, Shen, Wei, Michael, Chanu, Pascal
Format:	Journal Article
Language:	English
Published:	United States John Wiley & Sons, Inc 01.06.2024 John Wiley and Sons Inc Wiley
Subjects:	Adult Aged Aged, 80 and over Antibodies, Bispecific - administration & dosage Antibodies, Bispecific - immunology Antibodies, Bispecific - pharmacokinetics Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - pharmacokinetics Antigens, CD20 - immunology Antigens, CD20 - metabolism Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - pharmacokinetics Antineoplastic Agents, Immunological - therapeutic use Bispecific antibodies Body weight CD20 antigen Dosage Dose-Response Relationship, Drug Drug Administration Schedule Drug dosages Female Humans Immunotherapy Lymphocytes B Lymphocytes T Lymphoma Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - immunology Male Middle Aged Models, Biological Monoclonal antibodies Non-Hodgkin's lymphoma Patients Pharmacokinetics Rituximab Rituximab - administration & dosage Rituximab - pharmacokinetics Targeted cancer therapy Young Adult
ISSN:	1752-8054, 1752-8062, 1752-8062
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!